The role of F-18-fluorothymidine PET in oncology

Clinical and Translational Imaging

Volumn 1, Issue 2, 2013, Pages 77-97

  Bertagna, Francesco ^a   Biasiotto, Giorgio ^b   Giubbini, Raffaele ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

3 Deoxy 3 18 fluorothymidine; Oncology; Positron emission tomography computed tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM PENTETATE MEGLUMINE; GEFITINIB; KI 67 ANTIGEN; METHIONINE C 11; RADIOISOTOPE;

ACUTE GRANULOCYTIC LEUKEMIA; BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM TUMOR; HEAD AND NECK TUMOR; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SARCOMA; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84892812306     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-013-0014-2     Document Type: Review

References (104)

1. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43: 1210-1217.
2. Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D (1994) Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 170: 1394-1403.
3. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336.
4. Shields AF (2003) PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 44: 1432-1434.
5. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2): 64S-80S.
6. Buchmann I, Neumaier B, Schreckenberger M, Reske S (2004) [18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations-a pilot study. Cancer Biother Radiopharm 19: 436-442.
7. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, Mattfeldt T, Tepsic D, Bunjes D, Mottaghy FM, Krause BJ, Neumaier B, Döhner H, Möller P, Reske SN (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66: 11055-11061.
8. Alauddin MM (2012) Positron emission tomography (PET) imaging with 18F-based radiotracers. Am J Nucl Med Mol Imaging 2: 55-76.
9. Pascali C, Bogni A, Fugazza L, Cucchi C, Crispu O, Laera L, Iwata R, Maiocchi G, Crippa F, Bombardieri E (2012) Simple preparation and purification of ethanol-free solutions of 3′-deoxy-3′-[18F]fluorothymidine by means of disposable solid-phase extraction cartridges. Nucl Med Biol 39: 540-550.
10. Wilson IK, Chatterjee S, Wolf W (1991) Synthesis of 3′-fluoro-3′-deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. J Fluorine Chem 55: 283-289.
11. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-18Ffluorothymidine (18F-FLT). J Radioanal Nucl Chem 243: 843-846.
12. Grierson JR, Shields AF (2000) Radiosynthesis of 3′-deoxy-3′-18F-fluorothymidine: 18F-FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27: 143-156.
13. Oh SJ, Mosdzianowski C, Chi DY, Kim JU, Kang SH, Ryu JS, Yeo JS, Moon DH (2004) Fully automated synthesis system of 3′-deoxy-3′-18Ffluorothymidine. Nucl Med Biol 31: 803-809.
14. Reischl G, Blocker A, Wei R, Ehrlichmann W, Kuntzsch M, Solbach C, Dohmen BM, Machulla HJ (2006) Simplified, automated synthesis of 3′-18F-fluoro-3′-deoxy-thymidine (18F-FLT) and simple method for metabolite analysis in plasma. Radiochim Acta 94: 447-458.
15. Teng B, Wang S, Fu Z, Dang Y, Wu Z, Liu L (2006) Semiautomatic synthesis of 3′-deoxy-3′-18Ffluorothymidine using three precursors. Appl Radiat Isot 64: 187-193.
16. Nandy SK, Rajan MGR (2010) Fully automated and simplified radiosynthesis of [18F]-3′-deoxy-3′-fluorothymidine using anhydro precursor and single neutral alumina column purification. J Radioanal Nucl Chem 283: 741-748.
17. Tang G, Tang X, Wen F, Wang M, Li B (2010) A facile and rapid automated synthesis of 3′-deoxy-3′-[18F]fluorothymidine. Appl Radiat Isot 68: 1734-1739.
18. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO (2003) 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798.
19. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallières E, Wood DE (2002) In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8: 3315-3323.
20. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, Mattfeldt T, Liewald F, Reske SN, Neumaier B (2002) 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62: 3331-3334.
21. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44: 1426-1431.
22. Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL, Groen HM (2004) Is 18F-3′-fluoro-3′-deoxy-l-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 45: 1677-1682.
23. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, Wahl A, Glatting G, Mottaghy FM, Mattfeldt T, Neumaier B, Reske SN (2005) Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 32: 525-533.
24. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA (2006) Evaluation of thoracic tumours with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 129: 393-401.
25. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y, Ohkawa M (2007) Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34: 1610-1616.
26. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, Lee DH, Suh C, Lee JS, Kim SW (2008) [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14: 7423-7429.
27. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, Feng H, Tan Y, Zhao Z, Wu W (2008) A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 49: 186-194.
28. Yamamoto Y, Nishiyama Y, Ishikawa S, Gotoh M, Bandoh S, Kanaji N, Asakura M, Ohkawa M (2008) 3′-Deoxy-3′-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumours: comparison with 2-deoxy-2-18f-fluoro-d-glucose. J Comput Assist Tomogr 32: 432-437.
29. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, Kanaji N, Asakura M, Ohkawa M (2008) Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 35: 236-245.
30. Everitt S, Hicks RJ, Ball D, Kron T, Schneider-Kolsky M, Walter T, Binns D, Mac Manus M (2009) Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 75: 1098-1104.
31. Yang W, Zhang Y, Fu Z, Yu J, Sun X, Mu D, Han A (2010) Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 37: 1291-1299.
32. Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C (2011) Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 52: 1871-1877.
33. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM (2011) Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 17: 3304-3315.
34. Saga T, Koizumi M, Inubushi M, Yoshikawa K, Tanimoto K, Fukumura T, Miyamoto T, Nakajima M, Yamamoto N, Baba M (2011) PET/CT with 3′-deoxy-3′-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. Nucl Med Commun 32: 348-355.
35. Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, Ménard JF, Modzelewski R, Thiberville L, Dubray B (2011) Simultaneous positron emission tomography (PET) assessment of metabolism with 18-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18-fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 98: 109-116.
36. Xu B, Guan Z, Liu C, Wang R, Yin D, Zhang J, Chen Y, Yao S, Shao M, Wang H, Tian J (2011) Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions? Eur J Nucl Med Mol Imaging 38: 285-292.
37. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A, Heukamp L, Buettner R, Ko YD, Ullrich RT, Smit E, Boellaard R, Lammertsma AA, Hallek M, Jacobs AH, Schlesinger A, Schulte K, Querings S, Stoelben E, Neumaier B, Thomas RK, Dietlein M, Wolf J (2011) Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 29: 1701-1708.
38. Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M, Wolf J, Kahraman D (2012) Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 39: 1117-1127.
39. Yang W, Zhang Y, Fu Z, Sun X, Mu D, Yu J (2012) Imaging proliferation of 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 39: 1289-1296.
40. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, Taylor I, Ell PJ (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52: 1602-1606.
41. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, Taylor I, Ell PJ (2003) Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 30: 988-994.
42. van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, Plukker JT (2005) Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 46: 400-404.
43. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, Becker K, Schuster T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ (2007) Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48: 1945-1950.
44. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, Rummeny E, Siewert JR, Schwaiger M, Stollfuss J (2007) PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34: 878-883.
45. Herrmann K, Eckel F, Schmidt S, Scheidhauer K, Krause BJ, Kleeff J, Schuster T, Wester HJ, Friess H, Schmid RM, Schwaiger M, Buck AK (2008) In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumours. J Nucl Med 49: 1437-1444.
46. Quon A, Chang ST, Chin F, Kamaya A, Dick DW, Loo BW Jr, Gambhir SS, Koong AC (2008) Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging 35: 527-531.
47. Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM, Schwaiger M, Buck AK (2009) Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med 50: 1441-1447.
48. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M, Murota M, Kaji M, Haba R, Nishiyama Y (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36: 382-388.
49. 18F-FDG PET. Nucl Med Commun 30: 841-845.
50. Yue J, Chen L, Cabrera AR, Sun X, Zhao S, Zheng F, Han A, Zheng J, Teng X, Ma L, Ma Y, Han D, Zhao X, Mu D, Yu J, Li Y (2010) Measuring tumour cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med 51: 528-534.
51. Kameyama R, Yamamoto Y, Izuishi K, Sano T, Nishiyama Y (2011) Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer. Nucl Med Commun 32: 460-465.
52. Muijs CT, Beukema JC, Widder J, van den Bergh AC, Havenga K, Pruim J, Langendijk JA (2011) 18F-FLT-PET for detection of rectal cancer. Radiother Oncol 98: 357-359.
53. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, zum Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ (2011) Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 18: 3316-3323.
54. Dehdashti F, Grigsby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA (2012) Positron emission tomography with [(18)F]-3′-deoxy-3′fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol. doi: 10. 1007/s11307-012-0566-y.
55. Han D, Yu J, Zhong X, Fu Z, Mu D, Zhang B, Xu G, Yang W, Zhao S (2012) Comparison of the diagnostic value of 3-deoxy-3-(18) F-fluorothymidine and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study. Dis Esophagus 25: 416-426.
56. 18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging 39: 846-851.
57. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46: 945-952.
58. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, Ra YS, Yeo JS, Ryu JS, Moon DH (2005) [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumours. Eur J Nucl Med Mol Imaging 32: 653-659.
59. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss WD (2005) 18F-fluoro-l-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumours. J Nucl Med 46: 1948-1958.
60. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, Oya N, Mukai T, Hojo M, Hashimoto N, Manabe T, Hiraoka M, Togashi K (2006) Evaluation of primary brain tumours with FLT-PET: usefulness and limitations. Clin Nucl Med 31: 774-780.
61. Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE (2006) 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 8: 340-347.
62. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714-4721.
63. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T (2008) 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35: 2009-2017.
64. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, Neumaier B, Heiss WD, Wienhard K, Jacobs AH (2008) Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 14: 2049-2055.
65. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34: 878-883.
66. Hong IK, Kim JH, Ra YS, Kwon do H, Oh SJ, Kim JS (2011) Diagnostic usefulness of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in recurrent brain tumour. J Comput Assist Tomogr 35: 679-684.
67. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM (2012) Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 37: 854-861.
68. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM (2012) 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 14: 1079-1089.
69. Jeong SY, Lim SM (2012) Comparison of 3′-deoxy-3′-[(18)F]fluorothymidine PET and O-(2-[(18)F]fluoroethyl)-l-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol. doi: 10. 1016/j. nucmedbio. 2012. 02. 009.
70. Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T (2012) Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas. J Biomed Biotechnol 2012: 205818.
71. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53: 29-36.
72. Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer AJ, Hoekstra HJ, Jager PL, Elsinga PH (2004) 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med 45: 226-231.
73. Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, Bussink J, van der Kogel AJ, Oyen WJ, Kaanders JH (2007) 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48: 726-735.
74. Linecker A, Kermer C, Sulzbacher I, Angelberger P, Kletter K, Dudczak R, Ewers R, Becherer A (2008) Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 47: 80-85 (quiz N12).
75. Been LB, Hoekstra HJ, Suurmeijer AJ, Jager PL, van der Laan BF, Elsinga PH (2009) [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol 45: e211-e215.
76. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH (2010) 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumours. J Nucl Med 51: 866-874.
77. Troost EG, Bussink J, Slootweg PJ, Peeters WJ, Merkx MA, van der Kogel AJ, Oyen WJ, Kaanders JH (2010) Histopathologic validation of 3′-deoxy-3′-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl Med 51: 713-719.
78. Hoshikawa H, Nishiyama Y, Kishino T, Yamamoto Y, Haba R, Mori N (2011) Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol Imaging Biol 13: 172-177.
79. Inubushi M, Saga T, Koizumi M, Takagi R, Hasegawa A, Koto M, Wakatuki M, Morikawa T, Yoshikawa K, Tanimoto K, Fukumura T, Yamada S, Kamada T (2012) Predictive value of 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma. Ann Nucl Med. doi: 10. 1007/s12149-012-0652-x.
80. Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N (2012) Usefulness of 3′-Deoxy-3′-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med. doi: 10. 2967/jnumed. 111. 099200.
81. Agool A, Schot BW, Jager PL, Vellenga E (2006) 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med 47: 1592-1598.
82. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, Schuster T, Meyer zum Büschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13: 3552-3558.
83. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U (2007) Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 48: 746-753.
84. Buck AK, Bommer M, Juweid ME, Glatting G, Stilgenbauer S, Mottaghy FM, Schulz M, Kull T, Bunjes D, Möller P, Döhner H, Reske SN (2008) First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J Nucl Med 49: 1756-1762.
85. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U (2011) A pilot study to evaluate 3′-deoxy-3′-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 52: 1898-1902.
86. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, Ringshausen I, Rudelius M, Wester HJ, Schwaiger M, Keller U, Dechow T (2011) Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 52: 690-696.
87. Vanderhoek M, Juckett MB, Perlman SB, Nickles RJ, Jeraj R (2011) Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res 35: 310-316.
88. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, Wallwiener D, Bares R, Dohmen BM (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31: 720-724.
89. Been LB, Elsinga PH, de Vries J, Cobben DC, Jager PL, Hoekstra HJ, Suurmeijer AJ (2006) Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 32: 39-43.
90. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH (2006) Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8: 36-42.
91. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34: 1339-1347.
92. Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, Challapalli A, Turkheimer F, Al-Nahhas A, Sharma R, Coombes RC, Aboagye EO (2011) [18F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 17: 7664-7672.
93. Contractor K, Aboagye EO, Jacob J, Challapalli A, Coombes RC, Stebbing J (2012) Monitoring early response to taxane therapy in advanced breast cancer with circulating tumour cells and [(18)F] 3′-deoxy-3′-fluorothymidine PET: a pilot study. Biomark Med 6: 231-233.
94. Cobben DC, Jager PL, Elsinga PH, Maas B, Suurmeijer AJ, Hoekstra HJ (2003) 3′-18F-fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 44: 1927-1932.
95. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ, Bares R (2003) [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30: 1407-1412.
96. Cobben DC, Elsinga PH, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL, Hoekstra HJ (2004) Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res 10: 1685-1690.
97. Been LB, Suurmeijer AJ, Elsinga PH, Jager PL, van Ginkel RJ, Hoekstra HJ (2007) 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 48: 367-372.
98. Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN (2008) Imaging bone and soft tissue tumours with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res 14: 2970-2977.
99. Pfannenberg C, Aschoff P, Dittmann H, Mayer F, Reischl G, von Weyhern C, Kanz L, Claussen CD, Bares R, Hartmann JT (2010) PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumours? J Nucl Med 51: 845-853.
100. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J (2010) Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51: 340-346.
101. Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, Masson S, Walter T, Houzard C, Scoazec JY, Hervieu V, Vuillez JP, Cornu C, Janier M, Borson-Chazot F (2011) 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours. Nucl Med Commun 32: 91-97.
102. Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, DeLoia JA (2011) Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3′deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging. Nucl Med Biol 38: 485-491.
103. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC (2012) 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer 118: 3135-3144.
104. Yamane T, Takaoka A, Kita M, Imai Y, Senda M (2012) (18)F-FLT PET performs better than (18)F-FDG PET in differentiating malignant uterine corpus tumours from benign leiomyoma. Ann Nucl Med 26: 478-484.